Stryker stock gains from Raymond James support

Stryker Corp. stock (US8636671013) is trading against a fresh analyst backdrop on September 21, 2026, after MarketScreener reported that Raymond James reiterated a Buy rating and that the 28-analyst consensus target stands at USD 372.68, versus a last close of USD 275.12.

Analyst tone stays constructive

That gap is 35.46 percent, a concrete premium that keeps valuation expectations in view for investors. The same MarketScreener page also shows the stock down 2.96 percent for the year and 0.36 percent on the day at 274.13 USD in estimated Cboe BZX trading.

On the company side, the most recent report in the accessible set points to Q2 2026 revenue of USD 6.59 billion, up 9.4 percent year on year, and net income of USD 1.28 billion, or diluted EPS of USD 3.30, according to the external financial data page for Stryker Corp. The quarter ended June 30, 2026, which keeps those figures within the current reporting window.

June quarter anchors the story

That mix matters because the latest quarter combines growth with profitability: revenue rose 9.4 percent, while the reported EPS of USD 3.30 gives a second current operating marker. A third figure in the same set is operating cash flow of USD 5.04 billion in fiscal 2025, a historical comparison that shows the scale of cash generation behind the current valuation debate.

More news and analyses on Stryker Corp. stock

Stock level and backdrop

Stryker stock last closed at USD 275.12 on September 21, 2026 in the quoted consensus view, while the same data set puts the target at USD 372.68. For now, that leaves the shares priced well below the average target, with the analyst view and the June quarter both shaping sentiment.